FormsNet3 - Blank Form


 
 
Sequence Number:    

 
 
Date Received: __ __ __ __ - __ __- __ __  

 
 
CIBMTR Center Number:    

 
 
CIBMTR Recipient ID:    

 
 

Has this patient's data been previously reported to USIDNET?

  
 nmlkji

yes  
 nmlkji

no  

 
 
USIDNET ID:    

 
 
Today's Date: __ __ __ __ - __ __- __ __  

 
 
Date of HSCT for which this form is being completed: __ __ __ __ - __ __- __ __  

 

HSCT type (check all that apply): 

 
  

gfedcb
Autologous

 
 

  
gfedcb

Allogeneic, unrelated

 
 

  
gfedcb

Allogeneic, related

 
 

  
gfedcb

Syngeneic (identical twin)

 

Product type (check all that apply): 

 
  

gfedcb
Marrow

 
 

  
gfedcb

PBSC

 
 

  
gfedcb

Cord blood

 
 

  
gfedcb

Other product

 
 
Specify:    

 
 

Visit:

  
 nmlkji

100 day  
 nmlkji

6 months  
 nmlkji

1 year  
 nmlkji

2 years  
 nmlkji

> 2 years,  

 
 
Specify:    

 
 
1  Date of most recent hematologic testing: __ __ __ __ - __ __- __ __  

   
 
2  WBC:    

 

  
 nmlkji

x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
  

gfedcb
WBC not tested

  
 
3  Lymphocytes:    % 

 
  

gfedcb
Lymphocytes not tested

  
 
4  Eosinophils:    % 

 
  

gfedcb
Eosinophils not tested

  
 
5  Polymorphonuclear leukocytes (PMN):    % 

 
  

gfedcb
Polymorphonuclear leukocytes (PMN) not tested

    
 
6  Hemoglobin:    

 

  
 nmlkji

g/dL  
 nmlkji

g/L  
 nmlkji

mmol/L  

 
  

gfedcb
Hemoglobin not tested

 
  

gfedcb
transfused RBC < 30 days from date of test

    
 
7  Platelets:    

 

  
 nmlkji

x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
  

gfedcb
Platelets not tested

 
  

gfedcb
transfused platelets < 7 days from date of test

  Key Fields 

Laboratory Studies Post-HSCT Questions: 1 - 43

Form 2155 R2.0: Chronic Granulomatous Disease (CGD) Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2155 revision 2.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 1 / 15



   

Immunoglobulin Analysis 

Specify the most recent quantitative immunoglobulins measured since the date of the last report. 

For questions 8–13, also report immunoglobulins in the Form 2100 – 100 Days Post-HSCT Data beginning at question 55, or in the Form 2200 — Six Months to Two Years Post-
HSCT Data beginning at question 26. 

For questions 16–17, also report IVIG in the Form 2100 – 100 Days Post-HSCT Data beginning at question 61, or in the Form 2200 — Six Months to Two Years Post-HSCT Data 
beginning at question 32. 

 
8  IgG value:    

 

  
 nmlkji

mg/dL  
 nmlkji

g/dL  
 nmlkji

g/L  

 
  

gfedcb
IgG not tested

 
 
9  Date tested: __ __ __ __ - __ __- __ __  

   
 
10  IgM value    

 

  
 nmlkji

mg/dL  
 nmlkji

g/dL  
 nmlkji

g/L  

 
  

gfedcb
IgM not tested

 
 
11  Date tested: __ __ __ __ - __ __- __ __  

   
 
12  IgA value:    

 

  
 nmlkji

mg/dL  
 nmlkji

g/dL  
 nmlkji

g/L  

 
  

gfedcb
IgA not tested

 
 
13  Date tested: __ __ __ __ - __ __- __ __  

  
 
14  IgE value    IU/mL 

 
  

gfedcb
IgE not tested

 
 
15  Date tested: __ __ __ __ - __ __- __ __  

 
 

16  Did the recipient receive supplemental intravenous immunoglobulins (IVIG)(since the date of the last report)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

17  Was therapy ongoing within one month of immunoglobulin testing?

    
 nmlkji

yes  
 nmlkji

no  

 

Lymphocyte Analysis 

Specify the most recent lymphocyte assessment measured since the date of the last report. 

For questions 19 and 21–34, also report lymphocytes in the Form 2100 – 100 Days Post-HSCT Data beginning at question 71, or in the Form 2200 — Six Months to Two Years 
Post-HSCT Data beginning at question 42. 

 
18  Were lymphocyte analyses performed?

    
 nmlkji

yes  
 nmlkji

no  

 
 
19  Date of most recent testing performed: __ __ __ __ - __ __- __ __  

 
 
20  Absolute lymphocyte count value:    cells / µL (cells /mm3) 

 

 
 
21  CD3 (T cells) % of total lymphocytes    % 

   

-- or -- 
 
CD3 (T cells) value    

 

  
 nmlkji

x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
  

gfedcb
CD3 (T cells) not tested

 
 
22  CD4 (T helper cells) % of total lymphocytes    % 

   

-- or -- 
 
CD4 (T helper cells) value    

 

  
 nmlkji

x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
  

gfedcb
CD4 (T helper cells) not tested

 
 
23  CD8 (cytotoxic T cells) % of total lymphocytes    % 

Form 2155 R2.0: Chronic Granulomatous Disease (CGD) Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2155 revision 2.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 2 / 15



   

-- or -- 
 
CD8 (cytotoxic T cells) value:    

 

  
 nmlkji

x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
  

gfedcb
CD8 (cytotoxic T cells) not tested

 
 
24  CD20 (B lymphocyte cells) % of total lymphocytes    % 

   

-- or -- 
 
CD20 (B lymphocyte cells) value:    

 

  
 nmlkji

x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
  

gfedcb
CD20 (B lymphocyte cells) not tested

 
 
25  CD56 (natural killer (NK) cells) % of total lymphocytes    % 

   

-- or -- 
 
CD56 (natural killer (NK) cells) value    

 

  
 nmlkji

x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
  

gfedcb
CD56 (natural killer (NK) cells) not tested

 
 
26  CD4+/CD45RA+ (naive T cells) % of total lymphocytes    

   

-- or -- 
 
CD4+/CD45RA+ (naive T cells) value    

 
.

  
 nmlkji

x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
  

gfedcb
CD4+ / CD45RA+ (naive T cells) not tested

 
 
27  CD4+/CD45RO+ (memory T cells) % of total lymphocytes    % 

   

-- or -- 
 
CD4+/CD45RO+ (memory T cells) value    

 
.

  
 nmlkji

x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
  

gfedcb
CD4+/CD45RO+ (memory T cells) not tested

 

Antibody Response 

Specify the most recent antibody responses measured since the date of the last report. 

 
28  Date antibody responses were assessed: __ __ __ __ - __ __- __ __  

 
 

29  Diptheria

    
 nmlkji

Absent  
 nmlkji

Low  
 nmlkji

Normal  
 nmlkji

Not Tested  

 
 

30  Protein conjugated HIB or pneumococcal vaccine

    
 nmlkji

Absent  
 nmlkji

Low  
 nmlkji

Normal  
 nmlkji

Not Tested  

 
 

31  Tetanus

    
 nmlkji

Absent  
 nmlkji

Low  
 nmlkji

Normal  
 nmlkji

Not Tested  

  
 

32  Unconjugated pneumococcal polysaccharide:    / 
    

 # of serotypes producing  

a protective level 

 
.    

  Total serotypes tested from vaccine  

  
 

33  Conjugated pneumococcal polysaccharide:     / 
    

# of serotypes producing 

a protective level 

 
.    

  Total serotypes tested from vaccine  

Form 2155 R2.0: Chronic Granulomatous Disease (CGD) Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2155 revision 2.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 3 / 15



 

Lymphocyte Function 

Specify the most recent lymphocyte function measured since the date of the last report. 

 
34  Date lymphocyte function was assessed: __ __ __ __ - __ __- __ __  

 
 

35  Anti-CD3

    
 nmlkji

Absent  

 nmlkji
Low (10-30% of control)  

 nmlkji
Normal  

 nmlkji
Not tested  

 
 

36  Candida antigen

    
 nmlkji

Absent  

 nmlkji
Low (10-30% of control)  

 nmlkji
Normal  

 nmlkji
Not tested  

 
 

37  Concavalin A (ConA)

    
 nmlkji

Absent  

 nmlkji
Low (10-30% of control)  

 nmlkji
Normal  

 nmlkji
Not tested  

 
 

38  Phytohemagglutinin (PHA)

    
 nmlkji

Absent  

 nmlkji
Low (10-30% of control)  

 nmlkji
Normal  

 nmlkji
Not tested  

 
 

39  Pokeweed mitogen (PWM)

    
 nmlkji

Absent  

 nmlkji
Low (10-30% of control)  

 nmlkji
Normal  

 nmlkji
Not tested  

 
 

40  Tetanus antigen

    
 nmlkji

Absent  

 nmlkji
Low (10-30% of control)  

 nmlkji
Normal  

 nmlkji
Not tested  

 

Oxidative Burst 

Specify the most recent oxidative burst measured since the date of the last report. 

 
41  Date oxidative burst was assessed: __ __ __ __ - __ __- __ __  

Form 2155 R2.0: Chronic Granulomatous Disease (CGD) Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2155 revision 2.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 4 / 15



 
 
42  Neutrophils with normal respiratory burst:    % 

 
 
43  Specify evaluative technique used:    

 
 

44  Adenitis

    
 nmlkji

yes  
 nmlkji

no  

 
 
45  Organism:   

 
 
46  Specify other organism:    

 
 

47  If adenitis was present, was it a prominent feature of CGD?

    
 nmlkji

yes  
 nmlkji

no  

 
 

48  Brain abscess

    
 nmlkji

yes  
 nmlkji

no  

 
 
49  Organism   

 
 
50  Specify other organism:    

 
 

51  If brain abscess was present, was it a prominent feature of CGD?

    
 nmlkji

yes  
 nmlkji

no  

 
 

52  Cellulitis

    
 nmlkji

yes  
 nmlkji

no  

 
 
53  Organism   

 
 
54  Specify other organism:    

 
 

55  If cellulitis was present, was it a prominent feature of CGD?

    
 nmlkji

yes  
 nmlkji

no  

 
 

56  Furuncles

    
 nmlkji

yes  
 nmlkji

no  

 
 
57  Organism   

 
 
58  Specify other organism:    

 
 

59  If furuncles was present, was it a prominent feature of CGD?

    
 nmlkji

yes  
 nmlkji

no  

 
 

60  Genitourinary

    
 nmlkji

yes  
 nmlkji

no  

 
 
61  Organism   

 
 
62  Specify other organism:    

Clinical Features Assessed Post-HSCT Questions: 44 - 116

  Post-CGD Adenitis Infection Multiple (1) Questions: 45 - 46 

  Post-CGD Brain Abscess Multiple (1) Questions: 49 - 50 

  Post-CGD Cellulitis Multiple (1) Questions: 53 - 54 

  Post-CGD Furuncles Multiple (1) Questions: 57 - 58 

  Post-CGD Cenitourinary Multiple (1) Questions: 61 - 62 

Form 2155 R2.0: Chronic Granulomatous Disease (CGD) Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2155 revision 2.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 5 / 15



 
 

63  If genitourinary infection was present, was it a prominent feature of CGD?

    
 nmlkji

yes  
 nmlkji

no  

 
 

64  Impetigo

    
 nmlkji

yes  
 nmlkji

no  

 
 
65  Organism   

 
 
66  Specify other organism:    

 
 

67  If impetigo was present, was it a prominent feature of CGD?

    
 nmlkji

yes  
 nmlkji

no  

 
 

68  Joint

    
 nmlkji

yes  
 nmlkji

no  

 
 
69  Organism   

 
 
70  Specify other organism:    

 
 

71  If joint infection was present, was it a prominent feature of CGD?

    
 nmlkji

yes  
 nmlkji

no  

 
 

72  Liver abscess

    
 nmlkji

yes  
 nmlkji

no  

 
 
73  Organism   

 
 
74  Specify other organism:    

 
 

75  If liver abscess was present, was it a prominent feature of CGD?

    
 nmlkji

yes  
 nmlkji

no  

 
 

76  Lung abscess

    
 nmlkji

yes  
 nmlkji

no  

 
 
77  Organism   

 
 
78  Specify other organism:    

 
 

79  If lung abscess was present, was it a prominent feature of CGD?

    
 nmlkji

yes  
 nmlkji

no  

 
 

80  Lymph node abscess

    
 nmlkji

yes  
 nmlkji

no  

 
 
81  Organism   

 
 
82  Specify other organism:    

  Post-CGD Impetigo Multiple (1) Questions: 65 - 66 

  Post-CGD Joint Multiple (1) Questions: 69 - 70 

  Post-CGD Liver Abscess Multiple (1) Questions: 73 - 74 

  Post-CGD Lung Abscess Multiple (1) Questions: 77 - 78 

  Post-CGD Lymph Nodes Abscess Multiple (1) Questions: 81 - 82 

Form 2155 R2.0: Chronic Granulomatous Disease (CGD) Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2155 revision 2.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 6 / 15



 
 

83  If lymph nodes abscess was present, was it a prominent feature of CGD?

    
 nmlkji

yes  
 nmlkji

no  

 
 

84  Meningitis / encephalitis

    
 nmlkji

yes  
 nmlkji

no  

 
 
85  Organism:   

 
 
86  Specify other organism:    

 
 

87  If meningitis / encephalitis was present, was it a prominent feature of CGD?

    
 nmlkji

yes  
 nmlkji

no  

 
 

88  Osteomyelitis

    
 nmlkji

yes  
 nmlkji

no  

 
 
89  Organism   

 
 
90  Specify other organism:    

 
 

91  If osteomyelitis was present, was it a prominent feature of CGD?

    
 nmlkji

yes  
 nmlkji

no  

 
 

92  Perirectal abscess

    
 nmlkji

yes  
 nmlkji

no  

 
 
93  Organism   

 
 
94  Specify other organism:    

 
 

95  If perirectal abscess was present, was it a prominent feature of CGD?

    
 nmlkji

yes  
 nmlkji

no  

 
 

96  Pneumonia

    
 nmlkji

yes  
 nmlkji

no  

 
 
97  Organism:   

 
 
98  Specify other organism:    

 
 

99  If pneumonia was present, was it a prominent feature of CGD?

    
 nmlkji

yes  
 nmlkji

no  

 
 

100  Severe or protracted diarrhea

    
 nmlkji

yes  
 nmlkji

no  

 
 
101  Organism:   

 
 
102  Specify other organism:    

  Post-CGD Meningitis / Encephalitis Multiple (1) Questions: 85 - 86 

  Post-CGD Osteomyelitis Multiple (1) Questions: 89 - 90 

  Post-CGD Perirectal Abscess Multiple (1) Questions: 93 - 94 

  Post-CGD Pneumonia Multiple (1) Questions: 97 - 98 

  Post-CGD Diarrhea Multiple (1) Questions: 101 - 102 

Form 2155 R2.0: Chronic Granulomatous Disease (CGD) Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2155 revision 2.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 7 / 15



 
 

103  If severe or protracted diarrhea was present, was it a prominent feature of CGD?

    
 nmlkji

yes  
 nmlkji

no  

 
 

104  Subcutaneous abscess

    
 nmlkji

yes  
 nmlkji

no  

 
 
105  Organism   

 
 
106  Specify other organism:    

 
 

107  If subcutaneous abscess was present, was it a prominent feature of CGD?

    
 nmlkji

yes  
 nmlkji

no  

 
 

108  Systemic infection

    
 nmlkji

yes  
 nmlkji

no  

 
 
109  Organism:   

 
 
110  Specify other organism:    

 
 

111  If systemic infection was present, was it a prominent feature of CGD?

    
 nmlkji

yes  
 nmlkji

no  

 
 

112  Other infection

    
 nmlkji

yes  
 nmlkji

no  

 
 
113  Organism:   

 
 
114  Specify other organism:    

 
 
115  Specify other infection site:    

 
 

116  If other infection was present, was it a prominent feature of CGD?

    
 nmlkji

yes  
 nmlkji

no  

 
 

117  Did the recipient experience any of the following clinical features (since the date of the last report)?

    
 nmlkji

yes  
 nmlkji

no  

 
 

118  Is autoimmune hemolytic anemia present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

119  Is autoimmune hemolytic anemia prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

120  Is delayed puberty present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

121  Is delayed puberty prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

122  Is failure to thrive (weight<5th percentile) present?

    
 nmlkji

yes  
 nmlkji

no  

  Post-CGD Subcutaneous Abscess Multiple (1) Questions: 105 - 106 

  Post-CGD Systemic Infection Multiple (1) Questions: 109 - 110 

  Post-CGD Other Infection Multiple (1) Questions: 113 - 114 

  Clinical Status Post-HSCT Questions: 117 - 154

Form 2155 R2.0: Chronic Granulomatous Disease (CGD) Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2155 revision 2.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 8 / 15



 
 

123  Is failure to thrive (weight<5th percentile) prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

124  Is gastric outlet obstruction present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

125  Is gastric outlet obstruction prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

126  Is acute graft versus host disease present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

127  Is acute graft versus host disease prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

128  Is chronic graft versus host disease present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

129  Is chronic graft versus host disease prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

130  Is growth hormone deficiency present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

131  Is growth hormone deficiency prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

132  Is growth retardation (height<5th percentile) present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

133  Is growth retardation (height<5th percentile) prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

134  Is hypothyroidism present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

135  Is hypothyroidism prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

136  Is inflammatory bowel disease present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

137  Is inflammatory bowel disease prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

138  Is lymphoproliferative disease present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

139  Is lymphoproliferative disease prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

140  Is pulmonary fibrosis present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

141  Is pulmonary fibrosis prominent?

    
 nmlkji

yes  
 nmlkji

no  

Form 2155 R2.0: Chronic Granulomatous Disease (CGD) Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2155 revision 2.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 9 / 15



 
 

142  Is systemic inflammatory process present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

143  Is systemic inflammatory process prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

144  Is thrombocytopenia (< 100 x 109/L) present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

145  Is thrombocytopenia (< 100 x 109/L) prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

146  Is urinary outlet obstruction present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

147  Is urinary outlet obstruction prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

148  Is Veno-occlusive disease (VOD) present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

149  Is Veno-occlusive disease (VOD) prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

150  Are other clinical features present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

151  Are other features prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 
152  Specify other features:    

 
 

153  Did the recipient receive parenteral nutrition (since the date of the last report)?

    
 nmlkji

yes  
 nmlkji

no  

 
 

154  Did the recipient receive mechanical ventilation (since the date of the last report)?

    
 nmlkji

yes  
 nmlkji

no  

 
 

155  Was treatment given (since the date of the report)?

    
 nmlkji

yes  
 nmlkji

no  

 

Also report immunosuppressive medications given to prevent or treat GVHD in the corresponding questions on the Form 2000—Recipient Baseline Data, Form 2100—
100 Days Post-HSCT Data, Form 2200—Six Months to Two Years Post- HSCT Data, or Form 2300—Yearly Follow-Up for Greater Than Two Years Post-HSCT Data. 

Prophylactic drugs paused for < 1 week should not be considered as “Prophylactic Drug Stopped.” 

 
156  Were antifungal drug(s) given as prophylaxis?

    
 nmlkji

yes  
 nmlkji

no  

 
 

157  Were prophylactic antifungal drug(s) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
158  Date prophylactic antifungal drug(s) stopped: __ __ __ __ - __ __- __ __  

 
.

  
 nmlkji

date estimated  
 nmlkji

Date unknown  

 
 

159  Were antiviral drug(s) given as prophylaxis?

    
 nmlkji

yes  
 nmlkji

no  

  Post-HSCT Treatment for Chronic Granulomatous Disease Questions: 155 - 226

Form 2155 R2.0: Chronic Granulomatous Disease (CGD) Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2155 revision 2.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 10 / 15



 
 

160  Were prophylactic antiviral drug(s) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
161  Date prophylactic antivial drug(s) stopped: __ __ __ __ - __ __- __ __  

 
.

  
 nmlkji

date estimated  
 nmlkji

Date unknown  

 
 

162  Was co-trimoxazole (Bactrim, Septra) given as prophylaxis?

    
 nmlkji

yes  
 nmlkji

no  

 
 

163  Were co-trimoxazole (Bactrim, Septra) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
164  Date co-trimoxazole (Bactrim, Septra) stopped: __ __ __ __ - __ __- __ __  

 
.

  
 nmlkji

date estimated  
 nmlkji

Date unknown  

 

Therapy paused for < 1 week should not be considered as "Therapy Stopped." 
 

165  Was antithymocyte globulin (ATG, ATGAM, Thymoglobulin) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

166  Was therapeutic antithymocyte globulin (ATG, ATGAM, Thymoglobulin) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
167  Date therapeutic antithymocyte globulin (ATG, ATGAM, Thymoglobulin) stopped: __ __ __ __ - __ __- __ __  

 
.

  
 nmlkji

date estimated  

 nmlkji
Date unknown  

 
 

168  Were systemic corticosteroids given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

169  Were therapeutic systemic corticosteroids stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
170  Date therapeutic systemic corticosteroids stopped: __ __ __ __ - __ __- __ __  

 
.

  
 nmlkji

date estimated  
 nmlkji

Date unknown  

 
 

171  Were topical corticosteroids given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

172  Were therapeutic topical corticosteroids stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
173  Date therapeutic topical corticosteroids stopped: __ __ __ __ - __ __- __ __  

 
.

  
 nmlkji

date estimated  
 nmlkji

Date unknown  

 
 

174  Was cyclophosphamide (CTX, Cytoxan, Neosar) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

175  Was therapeutic cyclophosphamide (CTX, Cytoxan, Neosar) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
176  Date therapeutic cyclophosphamide (CTX, Cytoxan, Neosar) stopped: __ __ __ __ - __ __- __ __  

 
.

  
 nmlkji

date estimated  

 nmlkji
Date unknown  

Form 2155 R2.0: Chronic Granulomatous Disease (CGD) Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2155 revision 2.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 11 / 15



 
 

177  Was cyclosporine (CsA, Neoral, Sandimmune) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

178  Was therapeutic cyclosporine (CsA, Neoral, Sandimmune) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
179  Date therapeutic cyclosporine (CsA, Neoral, Sandimmune) stopped? __ __ __ __ - __ __- __ __  

 
.

  
 nmlkji

date estimated  

 nmlkji
Date unknown  

 
 

180  Was in vivo monoclonal antibody given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify monoclonal antibody: 
 

181  Was alemtuzumab (Campath) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

182  Was therapeutic alemtuzumab (Campath) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
183  Date therapeutic alemtuzumab (Campath) stopped: __ __ __ __ - __ __- __ __  

 
.

  
 nmlkji

date estimated  

 nmlkji
Date unknown  

 
 

184  Was daclizumab (anti-CD25, Zenapax) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

185  Was therapeutic daclizumab (anti-CD25, Zenapax) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
186  Date therapeutic daclizumab (anti-CD25, Zenapax) stopped: __ __ __ __ - __ __- __ __  

 
.

  
 nmlkji

date estimated  

 nmlkji
Date unknown  

 
 

187  Was etanercept (Enbrel) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

188  Was therapeutic etanercept (Enbrel) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
189  Date therapeutic etanercept (Enbrel) stopped: __ __ __ __ - __ __- __ __  

 
.

  
 nmlkji

date estimated  
 nmlkji

Date 
unknown  

 
 

190  Was infliximab (anti-TNF-α, Remicade) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

191  Was therapeutic infliximab (anti-TNF-α, Remicade) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
192  Date therapeutic infliximab (anti-TNF-α, Remicade) stopped: __ __ __ __ - __ __- __ __  

 
.

  
 nmlkji

date estimated  

 nmlkji
Date unknown  

Form 2155 R2.0: Chronic Granulomatous Disease (CGD) Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2155 revision 2.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 12 / 15



 
 

193  Was muromonab (anti-CD3, OKT3) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

194  Was therapeutic muromonab (anti-CD3, OKT3) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
195  Date therapeutic muromonab (anti-CD3, OKT3) stopped: __ __ __ __ - __ __- __ __  

 
.

  
 nmlkji

date estimated  

 nmlkji
Date unknown  

 
 

196  Was rituximab (anti-CD20, Rituxan, Mab Thera) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

197  Was therapeutic rituximab (anti-CD20, Rituxan, Mab Thera) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
198  Date therapeutic rituximab (anti-CD20, Rituxan, Mab Thera) stopped: __ __ __ __ - __ __- __ __  

 
.

  
 nmlkji

date estimated  

 nmlkji
Date unknown  

 
 

199  Was any other monoclonal antibody given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

200  Was therapeutic other monoclonal antibody stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
201  Date therapeutic other monoclonal antibody stopped: __ __ __ __ - __ __- __ __  

 
.

  
 nmlkji

date estimated  

 nmlkji
Date unknown  

 
 
202  Specify other monoclonal antibody:    

 
 

203  Was lenalidomide (Revlimid) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

204  Was therapeutic lenalidomide (Revlimid) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
205  Date therapeutic lenalidomide (Revlimid) stopped: __ __ __ __ - __ __- __ __  

 
.

  
 nmlkji

date estimated  
 nmlkji

Date unknown  

 
 

206  Was mycophenolate mofetil (MMF, Cellcept) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

207  Was therapeutic mycophenolate mofetil (MMF, Cellcept) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
208  Date therapeutic mycophenolate mofetil (MMF, Cellcept) stopped: __ __ __ __ - __ __- __ __  

 
.

  
 nmlkji

date estimated  
 nmlkji

Date 
unknown  

 
 

209  Was photopheresis / extracorporeal phototherapy (ECP)given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

210  Was therapeutic photopheresis / extracorporeal phototherapy (ECP) stopped?

    
 nmlkji

yes  
 nmlkji

no  

Form 2155 R2.0: Chronic Granulomatous Disease (CGD) Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2155 revision 2.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 13 / 15



  
 
211  Date therapeutic photopheresis / extracorporeal phototherapy (ECP) stopped: __ __ __ __ - __ __- __ __  

 
.

  
 nmlkji

date estimated  

 nmlkji
Date unknown  

 
 

212  Was sirolimus (Rapamune) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

213  Was therapeutic sirolimus (Rapamune) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
214  Date therapeutic sirolimus (Rapamune) stopped: __ __ __ __ - __ __- __ __  

 
.

  
 nmlkji

date estimated  
 nmlkji

Date unknown  

 
 

215  Was tacrolimus (FK506, Prograf) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

216  Was therapeutic tacrolimus (FK506, Prograf) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
217  Date therapeutic tacrolimus (FK506, Prograf) stopped: __ __ __ __ - __ __- __ __  

 
.

  
 nmlkji

date estimated  
 nmlkji

Date unknown  

 
 

218  Was thalidomide (Thalomid) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

219  Was therapeutic thalidomide (Thalomid)stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
220  Date therapeutic thalidomide (Thalomid)stopped: __ __ __ __ - __ __- __ __  

 
.

  
 nmlkji

date estimated  
 nmlkji

Date unknown  

 
 

221  Were other immunosuppressive drugs given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

222  Was the other therapeutic immunosuppressive drug stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
223  Date other therapeutic immunosuppressive drug stopped: __ __ __ __ - __ __- __ __  

 
.

  
 nmlkji

date estimated  
 nmlkji

Date unknown  

 
 
224  Specify other immunosuppressive drug:    

 
 

225  Did the recipient receive any other significant treatment(s) for CGD (since the date of the last report)?

    
 nmlkji

yes  
 nmlkji

no  

 
 
226  Specify other treatment(s):    

 
 

227  What is the current status of T-cell engraftment?

    
 nmlkji

predominantly or completely donor (>= 80% donor chimerism)  

 nmlkji
Mixed chimerism  

 nmlkji
only host T-cells detected (< 5% donor)  

 nmlkji
Unknown  

  
 
228  Most recent date T-cell engraftment was assessed: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date of most recent T-cell engraftment assessment unknown

Status of Hematologic Engraftment Questions: 227 - 232

Form 2155 R2.0: Chronic Granulomatous Disease (CGD) Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2155 revision 2.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 14 / 15



 
 

229  What is the current status of B-cell engraftment?

    
 nmlkji

predominantly or completely donor (>= 80% donor chimerism)  

 nmlkji
Mixed chimerism  

 nmlkji
only host B-cells detected (< 5% donor)  

 nmlkji
Unknown  

  
 
230  Most recent date B-cell engraftment was assessed: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date of most recent B-cell engraftment assessment unknown

 
 

231  What is the current status of myeloid engraftment?

    
 nmlkji

predominantly or completely donor (>= 80% donor chimerism)  

 nmlkji
Mixed chimerism  

 nmlkji
only host myeloid cells detected (< 5% donor)  

 nmlkji
Unknown  

  
 
232  Most recent date myeloid engraftment was assessed: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date of most recent myeloid engraftment assessment unknown

  
 
First Name:    

 
Last Name:    

   
 
Phone number:    

 
Fax number:    

 
E-mail address:    

Form 2155 R2.0: Chronic Granulomatous Disease (CGD) Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2155 revision 2.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 15 / 15